EMA Approves Second COVID-19 Vaccine as Moderna Receives Conditional Marketing Authorization in EU
核心洞察
The European Medicines Agency (搜索) (EMA) has recommended conditional marketing authorization for COVID-19 Vaccine Moderna, marking the second COVID-19 (搜索) vaccine approved for use in the European Union.
Clinical trial data from approximately 30,000 participants demonstrated 94.1% efficacy in preventing symptomatic COVID-19 (搜索), with maintained effectiveness across diverse populations including high-risk groups.
The mRNA (搜索)-based vaccine requires two doses administered 28 days apart and showed 90.9% efficacy in participants at risk of severe COVID-19 (搜索), including those with chronic conditions.
The European Medicines Agency (搜索) (EMA) has recommended granting conditional marketing authorization for COVID-19 Vaccine Moderna, providing the European Union with its second approved vaccine to combat the coronavirus pandemic. The recommendation from EMA's human medicines committee (CHMP) follows a thorough assessment of quality, safety, and efficacy data, paving the way for EU-wide vaccination campaigns.
"This vaccine provides us with another tool to overcome the current emergency," said Emer Cooke, Executive Director of EMA. "It is a testament to the efforts and commitment of all involved that we have this second positive vaccine recommendation just short of a year since the pandemic was declared by WHO."
Clinical Trial Results Demonstrate High Efficacy
The approval is based on results from a large-scale clinical trial involving approximately 30,000 participants. In this randomized, placebo-controlled study, half of the participants received the vaccine while the other half received dummy injections, with participants unaware of which treatment they received.
Efficacy analysis was conducted in around 28,000 people aged 18 to 94 years who showed no signs of previous COVID-19 (搜索) infection. The trial demonstrated a 94.1% reduction in symptomatic COVID-19 cases among vaccinated individuals, with only 11 out of 14,134 vaccinated people developing COVID-19 symptoms compared to 185 out of 14,073 people in the placebo group.
The vaccine showed particularly strong performance in high-risk populations, demonstrating 90.9% efficacy in participants at risk of severe COVID-19 (搜索), including those with chronic lung disease, heart disease, obesity, liver disease, diabetes, or HIV infection. The high efficacy was maintained across genders, racial, and ethnic groups.
mRNA Technology and Administration Protocol
COVID-19 Vaccine Moderna utilizes messenger RNA (搜索) (mRNA (搜索)) technology to prepare the body's immune system against SARS-CoV-2 (搜索). The vaccine contains mRNA instructions for producing the spike protein (搜索) found on the virus surface, which is essential for viral entry into human cells.
When administered, the vaccine causes some cells to temporarily produce the spike protein (搜索), prompting the immune system to recognize it as foreign and generate antibodies while activating T cells. This immune response prepares the body to defend against future SARS-CoV-2 (搜索) exposure. The mRNA (搜索) from the vaccine is broken down shortly after vaccination and does not remain in the body.
The vaccination protocol requires two injections administered into the arm 28 days apart. Clinical trial data showed that the most common side effects were generally mild to moderate and resolved within a few days. These included pain and swelling at the injection site, tiredness, chills, fever, swollen or tender lymph nodes under the arm, headache, muscle and joint pain, nausea, and vomiting.
Conditional Authorization Framework
The conditional marketing authorization represents a formal approval mechanism designed to facilitate early access to medicines addressing unmet medical needs during emergency situations. This authorization covers all vaccine batches produced for the EU and provides a robust regulatory framework for vaccination campaigns.
Under the conditional authorization terms, Moderna will continue providing results from the ongoing main trial for two years. These studies will evaluate protection duration, effectiveness against severe COVID-19 (搜索), protection for immunocompromised individuals, children, and pregnant women, and prevention of asymptomatic cases. Additional studies will ensure pharmaceutical quality as manufacturing scales up.
Enhanced Safety Monitoring
The vaccine will be subject to comprehensive safety monitoring aligned with the EU's safety monitoring plan for COVID-19 (搜索) vaccines. Companies must provide monthly safety reports beyond regular legislative requirements and conduct studies monitoring safety and effectiveness in real-world use.
Independent studies coordinated by EU authorities will provide additional long-term safety and benefit data in the general population. These measures enable regulators to rapidly assess emerging data from multiple sources and implement appropriate regulatory actions to protect public health when necessary.
The European Commission will now expedite the decision-making process to grant the conditional marketing authorization, enabling COVID-19 Vaccine Moderna to be deployed across EU vaccination programs alongside the previously approved Comirnaty vaccine from BioNTech and Pfizer.